378 related articles for article (PubMed ID: 15019015)
21. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients.
Ciccosanti F; Corazzari M; Soldani F; Matarrese P; Pagliarini V; Iadevaia V; Tinari A; Zaccarelli M; Perfettini JL; Malorni W; Kroemer G; Antinori A; Fimia GM; Piacentini M
Antivir Ther; 2010; 15(3):377-90. PubMed ID: 20516557
[TBL] [Abstract][Full Text] [Related]
23. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
Selwyn PA; Alcabes P; Hartel D; Buono D; Schoenbaum EE; Klein RS; Davenny K; Friedland GH
N Engl J Med; 1992 Dec; 327(24):1697-703. PubMed ID: 1359411
[TBL] [Abstract][Full Text] [Related]
24. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
25. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
Coplan PM; Cook JR; Carides GW; Heyse JF; Wu AW; Hammer SM; Nguyen BY; Meibohm AR; DiNubile MJ;
Clin Infect Dis; 2004 Aug; 39(3):426-33. PubMed ID: 15307012
[TBL] [Abstract][Full Text] [Related]
26. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials.
Rojas C; Coplan PM; Rhodes T; Robertson MN; DiNubile MJ; Guess HA
Pharmacoepidemiol Drug Saf; 2003; 12(5):361-9. PubMed ID: 12899109
[TBL] [Abstract][Full Text] [Related]
27. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
[TBL] [Abstract][Full Text] [Related]
28. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols].
Reszketö Z; Szlávik J; Balogh J; Vincze Z
Acta Pharm Hung; 2001 Dec; 71(4):428-32. PubMed ID: 12113183
[TBL] [Abstract][Full Text] [Related]
30. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Clumeck N
Antivir Ther; 1998; 3 Suppl 4():39-43. PubMed ID: 10723508
[TBL] [Abstract][Full Text] [Related]
31. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
32. Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
Braitstein P; Zala C; Yip B; Brinkhof MW; Moore D; Hogg RS; Montaner JS
J Infect Dis; 2006 Jan; 193(2):259-68. PubMed ID: 16362890
[TBL] [Abstract][Full Text] [Related]
33. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
[TBL] [Abstract][Full Text] [Related]
34. Race, sex, drug use, and progression of human immunodeficiency virus disease.
Chaisson RE; Keruly JC; Moore RD
N Engl J Med; 1995 Sep; 333(12):751-6. PubMed ID: 7643881
[TBL] [Abstract][Full Text] [Related]
35. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
[TBL] [Abstract][Full Text] [Related]
36. Duration of the survival benefit of zidovudine therapy in HIV infection.
Moore RD; Keruly JC; Chaisson RE
Arch Intern Med; 1996 May; 156(10):1073-7. PubMed ID: 8638994
[TBL] [Abstract][Full Text] [Related]
37. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
[TBL] [Abstract][Full Text] [Related]
38. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
39. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Dubé MP; Parker RA; Mulligan K; Tebas P; Robbins GK; Roubenoff R; Grinspoon SK
Clin Infect Dis; 2007 Jul; 45(1):120-6. PubMed ID: 17554712
[TBL] [Abstract][Full Text] [Related]
40. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
